Key Takeaways
- Shares of VIR climbed approximately 60% during Tuesday’s premarket session following announcement of a significant Astellas Pharma collaboration for VIR-5500, a prostate cancer treatment candidate
- The partnership brings $335M in immediate and near-term capital, with potential milestone payments reaching $1.37B
- Early-stage clinical data revealed an impressive 82% PSA50 response rate among patients receiving the highest dosage levels
- Fourth quarter results exceeded Wall Street expectations: 31-cent loss versus 41-cent forecast; $64.07M revenue versus $23.18M estimate
- Evercore ISI upgraded its valuation from $12 to $18 per share while reaffirming its Outperform recommendation
Vir Biotechnology reached its highest price point in 52 weeks during Tuesday’s early trading session, climbing nearly 60% as investors digested a simultaneous wave of favorable developments — a transformative pharmaceutical alliance, encouraging clinical trial outcomes, and better-than-anticipated financial results.
Premarket data from Benzinga Pro showed the stock advancing 59.49% to reach $11.85.
The primary catalyst came from a newly announced strategic alliance with Astellas Pharma centered on developing and bringing to market VIR-5500, an experimental therapy targeting prostate cancer. The financial structure includes $240M in immediate cash plus a $75M equity stake purchased at a 50% premium to market, delivering $335M in combined upfront value. Additionally, milestone-based payments could contribute another $1.37B over time.
Under the agreement terms, Astellas assumes primary responsibility for U.S. commercialization activities, while both companies will share profits and losses on a 50/50 basis.
Clinical Trial Results for VIR-5500
Newly released Phase 1 clinical findings for VIR-5500 provided additional momentum for the stock rally. The study enrolled patients with advanced metastatic castration-resistant prostate cancer who had exhausted several prior treatment options.
Among participants receiving the highest dose levels, an 82% PSA50 response rate was observed, while 53% achieved PSA90 reductions. When evaluating measurable disease, 45% of patients demonstrated objective responses according to RECIST assessment criteria.
Imaging studies using PSMA-PET scanning documented tumor reduction across various metastatic sites, including visceral disease locations.
The company outlined plans to initiate monotherapy expansion cohorts during the second quarter of 2026, with registrational Phase 3 studies anticipated to begin in 2027.
Fourth Quarter Financial Performance and Liquidity
Vir disclosed a fourth quarter loss of 31 cents per share, outperforming the Street consensus of a 41-cent deficit. Quarterly revenue totaled $64.07M, substantially surpassing analyst projections of $23.18M.
Factoring in the capital infusion from Astellas, the company now projects sufficient financial resources to fund operations into the second quarter of 2028.
Wall Street Response
Evercore ISI increased its price objective on VIR shares from $12 to $18, maintaining its Outperform stance. The research firm highlighted that the Astellas collaboration validates the commercial promise of VIR-5500 and noted the candidate’s apparently favorable safety characteristics compared to competing bispecific antibody programs.
Current analyst price targets for VIR span from $12 to $26 per share.
From a technical perspective, VIR was trading 12.3% above its 20-day simple moving average and 14.5% above its 100-day simple moving average entering Tuesday’s session. The relative strength index registered at a neutral 50 reading, while MACD indicators reflected modest bearish momentum beneath the signal line.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
